These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11221807)

  • 1. UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study.
    Krentz AJ
    Diabetes Obes Metab; 1999 Jan; 1(1):13-22. PubMed ID: 11221807
    [No Abstract]   [Full Text] [Related]  

  • 2. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study.
    Nathan DM
    Lancet; 1998 Sep; 352(9131):832-3. PubMed ID: 9742972
    [No Abstract]   [Full Text] [Related]  

  • 3. The continuing legacy of the United Kingdom Prospective Diabetes Study.
    Davis TM; Colagiuri S;
    Med J Aust; 2004 Feb; 180(3):104-5. PubMed ID: 14748669
    [No Abstract]   [Full Text] [Related]  

  • 4. The treatment of type 2 diabetes: good news from the UK.
    Smith RB; Mann JI
    N Z Med J; 1999 May; 112(1087):149-50. PubMed ID: 10378808
    [No Abstract]   [Full Text] [Related]  

  • 5. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
    Buysschaert M; Hermans MP
    Acta Clin Belg; 1999 Dec; 54(6):328-33. PubMed ID: 10686705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
    Holman RR
    Metabolism; 2006 May; 55(5 Suppl 1):S2-5. PubMed ID: 16631806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UKPDS and the legacy effect.
    Chalmers J; Cooper ME
    N Engl J Med; 2008 Oct; 359(15):1618-20. PubMed ID: 18843126
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 9. Unsubstantiated concerns over the safety of use of sulphonylureas and insulin for increased risk of diabetes complications.
    Weng J; Yang X
    J Diabetes; 2014 Jan; 6(1):30-2. PubMed ID: 23944992
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of the United Kingdom Prospective Diabetes Study.
    American Diabetes Association
    Diabetes Care; 2000 Jan; 23 Suppl 1():S27-31. PubMed ID: 12017673
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin: thoroughly modern therapy.
    Isley WL
    Endocr Pract; 2004; 10(3):289-90. PubMed ID: 15310550
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of metformin in type II diabetes.
    Epstein S
    Cleve Clin J Med; 1995; 62(5):278-9. PubMed ID: 7586481
    [No Abstract]   [Full Text] [Related]  

  • 13. Follow-up of intensive glucose control in type 2 diabetes.
    Lund SS; Rossing P; Vaag AA
    N Engl J Med; 2009 Jan; 360(4):416; author reply 418. PubMed ID: 19164195
    [No Abstract]   [Full Text] [Related]  

  • 14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 15. The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study.
    Matthews DR
    Diabetes Obes Metab; 1999 Sep; 1 Suppl 2():S7-13. PubMed ID: 11221801
    [No Abstract]   [Full Text] [Related]  

  • 16. Blood pressure control in type 2 diabetes--what does the United KingdomProspective Diabetes Study (UKPDS) tell us?
    Bilous R
    Nephrol Dial Transplant; 1999 Nov; 14(11):2562-4. PubMed ID: 10534485
    [No Abstract]   [Full Text] [Related]  

  • 17. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New agents available for the treatment of diabetes.
    Miller EC
    Home Care Provid; 1996; 1(6):312-4. PubMed ID: 9188302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.